The consumption of health products continues to upgrade, and the dividends of the related new medical regulation policies are gradually released. The biomedical technology industry is rapidly developing from the high-tech industry with the most development potential into a high-tech pillar industry. KPMG China launched the first selection of 50 biotechnology innovation enterprises in 2021, which attracted wide attention in the industry. It invited outstanding representatives from scientific research, industry, investment, enterprises and other fields to discuss the development of biotechnology innovation enterprises Adhering to its original mission, KPMG aims to support the development of China's biotech innovative enterprises by integrating diverse resources within the ecosystem, empowering win-win collaboration across the entire ecosystem, helping companies grasp policy directions and capitalize on development opportunities in the capital market, and assisting biotech companies at various stages in enhancing market visibility, thus achieving organic growth from within.
